MX2013001977A - Proteinas osteogenicas de diseño. - Google Patents

Proteinas osteogenicas de diseño.

Info

Publication number
MX2013001977A
MX2013001977A MX2013001977A MX2013001977A MX2013001977A MX 2013001977 A MX2013001977 A MX 2013001977A MX 2013001977 A MX2013001977 A MX 2013001977A MX 2013001977 A MX2013001977 A MX 2013001977A MX 2013001977 A MX2013001977 A MX 2013001977A
Authority
MX
Mexico
Prior art keywords
designer
osteogenic proteins
novel
designer osteogenic
cognate
Prior art date
Application number
MX2013001977A
Other languages
English (en)
Inventor
Stephen Peter Berasi
Christopher Todd Brown
Michael John Cain
Zong Sean Juo
Robert Vincent Paul Martinez
Howard Joel Seeherman
John Martin Wozney
Valerie Perrine Calabro
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720059&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013001977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2013001977A publication Critical patent/MX2013001977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a nuevas proteínas osteogénicas de diseño que tienen afinidad alterada por un receptor cognado, los ácidos nucleicos que codifican los mismos y métodos de uso de estos; con más preferencia, las nuevas proteínas osteogénica de diseño son BMP de diseño y tienen afinidad alterada por un receptor de BMP cognado; las BMP de diseño demuestran características biológicas alteradas y proporcionan nuevas terapéuticas útiles.
MX2013001977A 2010-08-20 2011-08-17 Proteinas osteogenicas de diseño. MX2013001977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37563610P 2010-08-20 2010-08-20
PCT/IB2011/053638 WO2012023113A2 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins

Publications (1)

Publication Number Publication Date
MX2013001977A true MX2013001977A (es) 2013-04-03

Family

ID=44720059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001977A MX2013001977A (es) 2010-08-20 2011-08-17 Proteinas osteogenicas de diseño.

Country Status (18)

Country Link
US (1) US8952131B2 (es)
EP (4) EP2605787B1 (es)
JP (4) JP5985480B2 (es)
KR (3) KR101767860B1 (es)
CN (2) CN103079585B (es)
AR (1) AR082502A1 (es)
AU (1) AU2011292810B2 (es)
BR (1) BR112013003587B1 (es)
CA (1) CA2807343C (es)
CO (1) CO6680686A2 (es)
HK (1) HK1184377A1 (es)
IL (3) IL224394A (es)
MX (1) MX2013001977A (es)
PE (1) PE20140135A1 (es)
RU (1) RU2013104029A (es)
SG (1) SG187589A1 (es)
TW (1) TWI444475B (es)
WO (1) WO2012023113A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
US9872881B2 (en) * 2013-11-01 2018-01-23 The Brigham And Women's Hospital, Inc. Bone and metal targeted polymeric nanoparticles
AU2015374114B2 (en) 2014-12-29 2018-07-26 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
CN107614526A (zh) 2015-06-05 2018-01-19 诺华股份有限公司 靶向骨形成蛋白9(bmp9)的抗体及其方法
AU2016310551A1 (en) * 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
EP3341398A2 (en) 2015-08-25 2018-07-04 Histide AG Compounds for inducing tissue formation and uses thereof
CA3002404A1 (en) 2015-10-23 2017-04-27 Bioventus, Llc Improved purification of tgf-beta superfamily proteins
US20170319750A1 (en) 2016-05-09 2017-11-09 Bioventus, Llc Composite matrices designed for enhanced bone repair
EP3468626A1 (en) * 2016-06-10 2019-04-17 Bioventus LLC Protein delivery with porous metallic structure
BR112019000941A2 (pt) 2016-07-20 2019-04-30 Novartis Ag derivados de aminopiridina e seu uso como inibidores seletivos de alk-2
CN106749606B (zh) 2016-12-29 2018-06-22 广州领晟医疗科技有限公司 一种用于修复软骨和/或治疗骨关节炎的肽
WO2018122794A1 (en) 2016-12-30 2018-07-05 Biogend Therapeutics Co., Ltd. Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
PE20201282A1 (es) 2017-11-24 2020-11-24 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2
US11529438B2 (en) 2018-06-25 2022-12-20 Bioventus, Llc Porous carrier matrix

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5688678A (en) 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
ES2137931T3 (es) 1990-06-15 2000-01-01 Carnegie Inst Of Washington Proteinas gdf-1 y uog-1.
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US5652337A (en) 1991-03-11 1997-07-29 Creative Biomolecules, Inc. OP-3-induced morphogenesis
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6025475A (en) 1998-09-15 2000-02-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69434875T2 (de) 1993-05-12 2007-09-06 Genetics Institute, LLC, Cambridge BMP-11 Zusammenstellungen
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
JPH09505991A (ja) 1993-10-08 1997-06-17 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子‐１０
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
JP4847634B2 (ja) 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
EP2128260A3 (en) * 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
DE60006356T2 (de) 1999-02-04 2004-09-09 SDGI Holding, Inc., Wilmington Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung
US7435260B2 (en) 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DE10026713A1 (de) 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
ES2319506T3 (es) 2000-10-24 2009-05-08 Warsaw Orthopedic, Inc. Metodos y dispositivos de fusion vertebral.
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2005116052A2 (en) 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7749268B2 (en) 2004-05-26 2010-07-06 Warsaw Orthopedic, Inc. Methods for treating the spine
EP1751185A2 (en) 2004-05-27 2007-02-14 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
EP1828232A2 (en) 2004-12-22 2007-09-05 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
WO2006125868A1 (en) 2005-05-27 2006-11-30 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
US7671014B2 (en) 2006-08-14 2010-03-02 Warsaw Orthopedic, Inc. Flowable carrier matrix and methods for delivering to a patient
WO2008051526A2 (en) 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
EP2222696A1 (en) 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
GB0818255D0 (en) * 2008-10-06 2008-11-12 Agency Science Tech & Res Isolation and identification of glycosaminoglycans
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
CA2772026C (en) 2009-08-31 2013-11-19 Nippon Steel Corporation High-strength galvanized steel sheet and method of manufacturing the same

Also Published As

Publication number Publication date
BR112013003587A2 (pt) 2016-06-07
EP3124039B1 (en) 2018-01-31
PE20140135A1 (es) 2014-02-20
JP2013538054A (ja) 2013-10-10
TW201226565A (en) 2012-07-01
EP2605787A2 (en) 2013-06-26
JP2016196478A (ja) 2016-11-24
CO6680686A2 (es) 2013-05-31
BR112013003587B1 (pt) 2022-11-08
EP3124039A3 (en) 2017-03-08
JP6317789B2 (ja) 2018-04-25
AR082502A1 (es) 2012-12-12
EP3320913B1 (en) 2019-11-27
JP2018126148A (ja) 2018-08-16
KR101800596B1 (ko) 2017-11-22
EP3320913A2 (en) 2018-05-16
WO2012023113A3 (en) 2012-04-12
CN103079585A (zh) 2013-05-01
AU2011292810A1 (en) 2013-02-07
US20120046227A1 (en) 2012-02-23
JP5985480B2 (ja) 2016-09-06
JP6142041B2 (ja) 2017-06-07
BR112013003587A8 (pt) 2017-12-26
IL224394A (en) 2017-11-30
CA2807343A1 (en) 2012-02-23
RU2013104029A (ru) 2014-09-27
KR101767860B1 (ko) 2017-08-14
IL254186A0 (en) 2017-10-31
US8952131B2 (en) 2015-02-10
EP2605787B1 (en) 2017-04-26
KR20130048782A (ko) 2013-05-10
KR20170094549A (ko) 2017-08-18
KR101630501B1 (ko) 2016-06-15
CA2807343C (en) 2018-05-22
KR20160062191A (ko) 2016-06-01
WO2012023113A2 (en) 2012-02-23
EP3124039A2 (en) 2017-02-01
JP2017029143A (ja) 2017-02-09
EP3320913A3 (en) 2018-07-25
EP2949338A1 (en) 2015-12-02
HK1184377A1 (zh) 2014-01-24
CN103079585B (zh) 2015-09-30
TWI444475B (zh) 2014-07-11
CN105198981A (zh) 2015-12-30
CN105198981B (zh) 2019-07-16
EP2949338B1 (en) 2017-10-25
IL261608A (en) 2018-10-31
SG187589A1 (en) 2013-03-28
AU2011292810B2 (en) 2015-04-30
IL261608B (en) 2019-05-30

Similar Documents

Publication Publication Date Title
MX2013001977A (es) Proteinas osteogenicas de diseño.
LTC2059534I2 (lt) Genų inžinerijos būdu pagaminti anti-IL-23P19 antikūnai
WO2011047146A3 (en) Methods of affinity maturing antibodies
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
EP2558478A4 (en) MODIFIED PYRIMIDINES IN POSITION 5 AND THEIR USE
FR2945538B1 (fr) Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
BRPI0923731A2 (pt) "formulações injetáveis de toxinas botulínicas".
DE602007012072D1 (de) Orantagonisten
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
BRPI1013688A2 (pt) proteínas de ligação de il-17.
FR2943680B1 (fr) Composition de caoutchoux et pneumatique utilisant cette composition.
WO2013138793A3 (en) Affinity reagants for protein purification
BRPI0922461A2 (pt) superfície do estabilizador horizontal de aeronave.
ATE534722T1 (de) Hydrophob modifizierte polyalkylenimine als farbübertragungsinhibitoren
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
BR112013009083A8 (pt) anticorpos humanos de oncostatin m e métodos de uso
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
NL2000380A1 (nl) 3-aminocyclopentaancarboxamiden als modulatoren van chemokine-receptoren.
BR112012002596A2 (pt) formulações de polipeptídeo concentradas com viscodidade reduzida
BRPI1009519A2 (pt) 3-amino-2-mercaptoquinolina substituída como modulador de kcnq2/3.
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
IT1392200B1 (it) Stabilizzatore vertebrale modulare.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal